Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Obsidian Therapeutics, Inc.OBX · Entity 4898 | Director | August 03, 2026 | August 05, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Obsidian Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2036-08-02 | Direct | 37,653 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 37,653 · Balance 37,653 F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Xilio Therapeutics, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.99 · Expires 2036-06-10 | Direct | 5,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 5,000 · Balance 5,000 F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Surface Oncology, Inc.
Report date September 08, 2023 · Filed September 08, 2023
Section 16 reporting ended · disclosed 2023-09-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-08 transaction · row 1
1 source rowRow 1 · 2023-09-08 · Disposition to issuer · Disposed 83,193 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 | Direct | 0 |
Reported balance
After 2023-09-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-08 · Disposition to issuer · Disposed 400,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F3: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc.
F3: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:10 UTC | Obsidian Therapeutics, Inc. OBX · Entity 4898 | GrantStock Option (Right to Buy) · Derivative | 37,653 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001193125-26-335113 · ownership.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,653 Underlying: Common Stock · 37,653 shares Expires 2036-08-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:07 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001193125-26-269397 · ownership.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:37 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 31,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001415889-25-016972 · form4-06122025_080633.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017207 · form4-06172024_040611.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 16:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001209191-23-048757 · doc4.xml · derivative · entry 2 ROSS ROBERT W. · CIK 0001733077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F3 · derivative.exercise_date: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option. F3 · derivative.expiration_date: At the Effective Time, each option to purchase shares of the Issuer's Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $1.0354 (any such option, an "In-the-Money Option") was cancelled and converted into the right to receive (i) 0.1960 shares of common stock of Coherus and (ii) a number of CVRs equal to the number of shares of Surface common stock underlying such In-the-Money Option. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 16:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Disposition to issuerCommon Stock | 83,193 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-048757 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc. Read SEC document |
| August 01, 2023 Filed Aug 11, 2023 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 16,713 | $0.94 | $15,710.22 |
DisclosureSEC source: 0001209191-23-045494 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,193 F1 · kind: Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009741 · form4-06132023_040623.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001209191-23-016052 · doc4.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The Options shall vest in full on February 8, 2024, so long as the reporting person remains an employee or other service provider of the Issuer on such date. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 10,594 | $1.72 | $18,221.68 |
DisclosureSEC source: 0001209191-22-044673 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,906 F1 · kind: Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:08 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 26,400 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006704 · form4-06172022_010602.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option award was granted on June 15, 2022 and will vest in three equal installments on June 15, 2023, June 15, 2024 and June 15, 2025. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 359,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001209191-22-015966 · doc4.xml · derivative · entry 2 ROSS ROBERT W. · CIK 0001733077 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,000 Underlying: Common Stock · 359,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: The option vests in equal monthly installments over four years, so that all of the underlying shares shall be vested on February 8, 2026, so long as the reporting person remains an employee or other service provider of the Issuer on such dates. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantCommon Stock | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015966 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,500 F1 · kind: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest as follows: 40% on August 1, 2022 and the remaining 60% on August 1, 2023, so long as the reporting person remains an employee or other service provider of the Issuer on such date. Read SEC document |
| July 21, 2021 Filed Jan 14, 2022 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 33,500 | $6.10 | $204,350.00 |
DisclosureSEC source: 0001209191-22-003397 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 F1 · kind: Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 1,000 | $11.35 | $11,350.00 |
DisclosureSEC source: 0001209191-21-012182 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. Read SEC document |
| February 12, 2021 Filed Mar 3, 2021 20:18 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 484,280 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0001209191-21-017481 · doc4.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,280 Underlying: Common Stock · 484,280 shares Expires 2031-02-12 F1 · derivative.exercise_date: This option shall become exercisable in equal monthly installments over four years following February 9, 2021, so long as the reporting person remains an employee or other service provider of the Company on such dates. Read SEC document |
| February 12, 2021 Filed Mar 11, 2021 20:00 UTC Amendment | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 484,280 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0001209191-21-019971 · doc4a.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484,280 Underlying: Common Stock · 484,280 shares Expires 2031-02-12 F1 · derivative.exercise_date: This Amendment to the Form 4 filed by the reporting person on March 3, 2021 is filed to correct the vesting schedule previously reported in Table II. This option shall become exercisable in equal monthly installments over four years following April 1, 2021, so long as the reporting person remains an employee or other service provider of the Company on such dates. Read SEC document |
| January 15, 2021 Filed Jan 15, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 2,000 | $12.25 | $24,500.00 |
DisclosureSEC source: 0001209191-21-003916 · doc4.xml · nonDerivative · entry 2 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 7,000 | $11.95 | $83,650.00 |
DisclosureSEC source: 0001209191-21-003916 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 1,000 | $10.48 | $10,480.00 |
DisclosureSEC source: 0001209191-20-064253 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 1,405 | $10.05 | $14,120.25 |
DisclosureSEC source: 0001209191-20-063630 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 595 | $10.05 | $5,979.75 |
DisclosureSEC source: 0001209191-20-058406 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,405 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 20:02 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 4,000 | $10.05 | $40,200.00 |
DisclosureSEC source: 0001209191-20-055191 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2020. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001209191-20-006846 · doc4.xml · derivative · entry 2 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006846 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 F1 · kind: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in full on the date 18 months after January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 18:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001209191-19-015872 · doc4.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-03-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments after February 12, 2019. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 16:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000899243-19-000741 · doc4.xml · derivative · entry 2 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,578 Underlying: Common Stock · 25,000 shares Expires 2026-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable with respect to the first 25% of the option grant on November 7, 2017, and the remainder vests and becomes exercisable in 36 equal monthly installments thereafter until November 7, 2020. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 16:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionCommon Stock | 25,000 | $4.14 | $103,400.00 |
DisclosureSEC source: 0000899243-19-000741 · doc4.xml · nonDerivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.